Rhaeos

Rhaeos operates in the medical technology sector, focusing on developing noninvasive wearable sensors designed to monitor hydrocephalus patients in real-time. The company primarily serves healthcare providers, including hospitals and clinics, that treat patients suffering from hydrocephalus, a condition characterized by an accumulation of cerebrospinal fluid within the brain. Rhaeos's core product aims to provide a reliable and efficient method for monitoring shunt function, which is critical for managing hydrocephalus. The company operates on a B2B (business-to-business) model, selling its sensors directly to healthcare institutions. Revenue is generated through the sale of these sensors and potentially through service agreements for ongoing monitoring and data analysis.

Rhaeos's market is primarily in the United States, where approximately 1,000,000 individuals are affected by hydrocephalus. The company is currently in the investigational stage, with products not yet approved by the FDA. However, it has garnered significant attention and accolades, including winning the Gold Award at the MedTech Conference in 2020 and the HealthTECH Startup Competition in 2019.

Keywords: hydrocephalus, wearable sensors, real-time monitoring, medical technology, noninvasive, healthcare providers, shunt function, B2B, FDA investigational, MedTech awards.